oral IDO1 inhibitor

clinical candidate in Ph. I/II combo for cancer

reversed amide of linrodostat

ACS Med. Chem. Lett., Jan. 28, 2021

Bristol Myers Squibb, Lawrence Township, NJ

The BMS IDO1 inhibitor, BMS-986242, is a clinical candidate in a Ph. I/II study in combination with nivolumab for cancer. Like me, you probably had to look twice at…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks